Erin Goss
Adult Health · Hackett, ARNPI 1386096584
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 126 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AbbVie at 27.2% of the total. Reporting peaked in 2021 at $1,281 and has fallen 82.2% since, to $228 in 2025.
Across 126 payments — averaging $21.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$747
- Lilly USA, LLC$258
- Novo Nordisk$224
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$207
- Amgen$204
- Pfizer$169
- plus $934 from 21 others
What the payments were for
- Food & beverage$2,742100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 33 | $747 |
| Lilly USA, LLC | 19 | $258 |
| Novo Nordisk | 6 | $224 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $207 |
| Amgen(2 entities) | 12 | $204 |
| Pfizer | 7 | $169 |
| GSK | 2 | $138 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $128 |
| Sanofi-aventis U.S. LLC | 4 | $77 |
| Novartis | 5 | $74 |
| Masimo Corporation | 1 | $61 |
| Merck | 4 | $58 |
| Phathom Pharmaceuticals, Inc. | 2 | $44 |
| Johnson & Johnson | 2 | $39 |
| Daiichi Sankyo Inc. | 2 | $35 |
| AstraZeneca | 2 | $33 |
| Biohaven Pharmaceuticals, Inc. | 2 | $32 |
| Shield Therapeutics Inc | 2 | $32 |
| Otsuka America Pharmaceutical, Inc. | 2 | $32 |
| Arbor Pharmaceuticals, Inc. | 2 | $31 |
| Sunovion Pharmaceuticals Inc. | 1 | $23 |
| Abiomed | 1 | $21 |
| Boehringer Ingelheim | 1 | $17 |
| Exact Sciences | 1 | $17 |
| Dexcom, Inc. | 1 | $16 |
| IBSA Pharma Inc. | 1 | $13 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$228
- VRAYLAR$125
- TRELEGY ELLIPTA$125
- CAPLYTA$125
- RYBELSUS$125
How this compares
$2,743 in reported general payments places this provider in the 80th percentile of 154 adult health providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 74 | $81,819 |
| JardianceEmpagliflozin | 32 | $33,490 |
| MounjaroTirzepatide | 27 | $29,356 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $21,144 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 76 | $2,290 |
| Estradiol (Once Weekly)Estradiol | 20 | $1,661 |
| Ondansetron OdtOndansetron | 15 | $888 |
| Omeprazole | 56 | $759 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 29 | $705 |
| Gabapentin | 39 | $657 |
| ProgesteroneProgesterone, Micronized | 20 | $528 |
| Testosterone Cypionate | 17 | $521 |
| Pantoprazole Sodium | 23 | $496 |
| Atorvastatin Calcium | 65 | $484 |
| Buprenorphine Hcl | 12 | $456 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $224 | $81,81974 claims |
| Boehringer IngelheimJardiance | $17 | $33,49032 claims |
| Lilly USA, LLCMounjaro | $258 | $29,35627 claims |
| GSKTrelegy Ellipta | $138 | $21,14421 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 154 adult health providers in Arkansas.
Other adult health in Hackett
- Holly MooreLittle Rock$59K
- Deborah ShipmanJonesboro$41K
- Lisa HurdJonesboro$12K
- Kari SchrankFayetteville$9K
- Amanda McClureFayetteville$9K
- Gina NullFort Smith$8K
- Darren CompasBentonville$8K
- Lisa HarveyHot Springs$8K
- Abby MartensSpringdale$7K
- Marie JonesFayetteville$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.